J Pharm Sci 93:15371544 [DOI] [PubMed] [Google Scholar] Ebens A, Brose K, Leonardo ED, Hanson MG, Jr, Bladt F, Birchmeier C, Barres BA, Tessier-Lavigne M
The LR3 refers to a modification of the peptide chain that significantly increases its half-life in the body, making it more stable and potent for research purposes compared to standard IGF-1.
At the middle dose, most animals showed minimal to mild lesions
The gut also makes many messenger chemicals used by the brain
A 26-week diabetes study measured human activity at 1 mg, but its endpoint was blood sugar rather than long-term weight. A short outpatient cohort measured about 4.7% weight loss over four weeks at 2.5 mg. Below 1 mg, estimates rely on pharmacokinetics and mechanism